Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6010 + enlonstobart
- Development stage
- Unknown
- Lead developer
- CSPC Megalith Biopharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SYS6010 + enlonstobart is a combination therapy being developed by CSPC Megalith Biopharmaceutical for the treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC). SYS6010 is an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), consisting of an anti-EGFR monoclonal antibody linked to a Dxd analogue payload (JS1) via a cleavable GGFG tetrapeptide linker with a drug-antibody ratio (DAR) of 8. Enlonstobart (SG001) is a recombinant, fully human monoclonal antibody that acts as a PD-1 checkpoint inhibitor. This combination is currently being evaluated in Phase 2/3 clinical trials as a first-line treatment for ESCC, often administered alongside chemotherapy such as 5-fluorouracil or capecitabine. The dual approach aims to leverage the targeted cytotoxicity of the ADC and the immune-potentiating effects of the PD-1 inhibitor.
- Brand names
- Enlonstobart
- Other names
- SYS6010 + SG001
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)PDCD1 (Programmed cell death protein 1 receptor)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on SYS6010 + enlonstobart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6010 + enlonstobart.